Paper42579877
Early EGFR Inhibition Triggers Actionable Tumor and Microenvironmental Remodeling in Lung Cancer.
Tan AC and 27 others. Cancer Res Commun, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Early EGFR Inhibition Triggers Actionable Tumor and Microenvironmental Remodeling in Lung Cancer. Papers, record 42579877. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42579877
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Early EGFR Inhibition Triggers Actionable Tumor and Microenvironmental Remodeling in Lung Cancer.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Tumor Microenvironment | Major topic |
| Lung Neoplasms | Major topic |
| Gefitinib | Major topic |
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Protein Kinase Inhibitors | Major topic |
| Humans | |
| ErbB Receptors | |
| Female | |
| Male | |
| Middle Aged | |
| Aged | |
| Mutation | |
| Neoadjuvant Therapy | |
| Adult |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| NMRC/TCR/007-NCC/2013 | National Medical Research Council (NMRC) | PubMed | ||
| NMRC/CSA/007/2016 | National Medical Research Council (NMRC) | PubMed | ||
| Fellowship 2018 | International Association for the Study of Lung Cancer (IASLC) | PubMed |
Source PubMed
References62
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37937763 | Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. | N Engl J Med | 2023 | https://conductscience.org/library/papers/37937763 | PubMed |
| 2 | 31194613 | Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study. | J Clin Oncol | 2019 | https://conductscience.org/library/papers/31194613 | PubMed |
| 3 | 30242021 | A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing. | Cancer Immunol Res | 2018 | https://conductscience.org/library/papers/30242021 | PubMed |
| 4 | 34278827 | Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA. | Future Oncol | 2021 | https://conductscience.org/library/papers/34278827 | PubMed |
| 5 | 24384493 | Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. | Lancet Oncol | 2014 | https://conductscience.org/library/papers/24384493 | PubMed |
| 6 | 31413010 | Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial. | Clin Cancer Res | 2019 | https://conductscience.org/library/papers/31413010 | PubMed |
| 7 | 16670306 | OX40-OX40 ligand interaction through T cell-T cell contact contributes to CD4 T cell longevity. | J Immunol | 2006 | https://conductscience.org/library/papers/16670306 | PubMed |
| 8 | 29335443 | Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing. | Nat Commun | 2018 | https://conductscience.org/library/papers/29335443 | PubMed |
| 9 | 24078774 | Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. | Cancer Discov | 2013 | https://conductscience.org/library/papers/24078774 | PubMed |
| 10 | 31061481 | Determining cell type abundance and expression from bulk tissues with digital cytometry. | Nat Biotechnol | 2019 | https://conductscience.org/library/papers/31061481 | PubMed |
| 11 | 37649478 | Tumor-associated macrophages mediate resistance of EGFR-TKIs in non-small cell lung cancer: mechanisms and prospects. | Front Immunol | 2023 | https://conductscience.org/library/papers/37649478 | PubMed |
| 12 | 31486833 | Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone in Patients With Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Phase 2 Randomized Clinical Trial. | JAMA Oncol | 2019 | https://conductscience.org/library/papers/31486833 | PubMed |
| 13 | 15173831 | Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. | Nat Rev Immunol | 2004 | https://conductscience.org/library/papers/15173831 | PubMed |
| 14 | 29045514 | Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy. | Ann Oncol | 2017 | https://conductscience.org/library/papers/29045514 | PubMed |
| 15 | 29871672 | Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. | J Immunother Cancer | 2018 | https://conductscience.org/library/papers/29871672 | PubMed |
| 16 | 19097774 | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). | Eur J Cancer | 2009 | https://conductscience.org/library/papers/19097774 | PubMed |
| 17 | 22753915 | Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer. | J Clin Oncol | 2012 | https://conductscience.org/library/papers/22753915 | PubMed |
| 18 | 35183043 | Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations. | ESMO Open | 2022 | https://conductscience.org/library/papers/35183043 | PubMed |
| 19 | 26313928 | Escher: A Web Application for Building, Sharing, and Embedding Data-Rich Visualizations of Biological Pathways. | PLoS Comput Biol | 2015 | https://conductscience.org/library/papers/26313928 | PubMed |
| 20 | 37340841 | Tumor Microenvironment Modulation by Neoadjuvant Erlotinib Therapy and Its Clinical Impact on Operable EGFR-Mutant Non-Small Cell Lung Cancer. | Cancer Res Treat | 2024 | https://conductscience.org/library/papers/37340841 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42579877
GET https://conductscience.org/api/papers/v1/42579877/authors?page=2